ACM
ENZN

Ativo Capital Management’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Ativo Capital Management’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-416,564
Closed -$575K – 240
2015
Q2 		$575K Buy
+416,564
New +$531K 0.2% 101

Other funds holding ENZN

IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Ativo Capital Management's ENZN Position: Q3 2015 in Review

Ativo Capital Management sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q3 2015, closing a stake of 416,564 shares — an estimated $575K sold.

Ativo Capital Management first reported a position in ENZN in Q2 2015 and held it in 1 quarter. The position peaked at $575K in Q2 2015. 53 funds tracked by Wall St. Rank hold ENZN as of Q3 2015.

  • Ativo Capital Management reported no remaining ENZON PHARMACEUTICALS INC position as of Q3 2015 after selling out during the quarter.
  • Ativo Capital Management sold 416,564 ENZON PHARMACEUTICALS INC shares in Q3 2015, an estimated $575K.
  • Ativo Capital Management first reported a position in ENZON PHARMACEUTICALS INC in Q2 2015 and held it in 1 quarter.
  • Ativo Capital Management's ENZON PHARMACEUTICALS INC position peaked at $575K in Q2 2015.
  • 53 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q3 2015.

Based on Ativo Capital Management's 13F filing for Q3 2015, filed 12 Nov 2015.